RCKT Rocket Pharmaceuticals Inc
Price (delayed)
$6.3
Market cap
$671.77M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.73
Enterprise value
$531.74M
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it
Highlights
The quick ratio has surged by 55% since the previous quarter and by 19% year-on-year
Rocket Pharmaceuticals's EPS has increased by 7% YoY
The equity has increased by 40% since the previous quarter but it has declined by 6% year-on-year
RCKT's net income is down by 5% YoY
Key stats
What are the main financial stats of RCKT
Market
Valuations
Earnings
Shares outstanding
106.63M
Market cap
$671.77M
Enterprise value
$531.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.24
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$273.21M
Net income
-$258.75M
EBIT
-$256.86M
EBITDA
-$247.49M
Free cash flow
-$215.59M
Per share
Balance sheet
Liquidity
EPS
-$2.73
EPS diluted
-$2.73
Free cash flow per share
-$2.27
Book value per share
$5.08
Revenue per share
$0
TBVPS
$4.89
Total assets
$527.7M
Total liabilities
$64.47M
Debt
$25.5M
Equity
$463.23M
Working capital
$337.5M
Debt to equity
0.06
Current ratio
9.3
Quick ratio
9.2
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-55.4%
Return on equity
-63.9%
Return on invested capital
-82.1%
Return on capital employed
-52.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCKT stock price
How has the Rocket Pharmaceuticals stock price performed over time
Intraday
8.43%
1 week
-18.08%
1 month
-33.33%
1 year
-75.49%
YTD
-49.88%
QTD
-5.55%
Financial performance
How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$273.21M
Net income
-$258.75M
Gross margin
N/A
Net margin
N/A
RCKT's net income is down by 5% YoY
The operating income has contracted by 5% YoY
Growth
What is Rocket Pharmaceuticals's growth rate over time
Valuation
What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.24
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 7% YoY
The stock's price to book (P/B) is 75% less than its last 4 quarters average of 4.5 and 72% less than its 5-year quarterly average of 4.1
The equity has increased by 40% since the previous quarter but it has declined by 6% year-on-year
Efficiency
How efficient is Rocket Pharmaceuticals business performance
RCKT's ROE is down by 23% YoY and by 2.1% from the previous quarter
The return on assets has declined by 21% year-on-year and by 2.2% since the previous quarter
The ROIC has contracted by 21% YoY and by 11% from the previous quarter
Dividends
What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCKT.
Financial health
How did Rocket Pharmaceuticals financials performed over time
The quick ratio has surged by 55% since the previous quarter and by 19% year-on-year
Rocket Pharmaceuticals's current ratio has surged by 54% QoQ and by 19% YoY
The debt is 94% smaller than the equity
The equity has increased by 40% since the previous quarter but it has declined by 6% year-on-year
Rocket Pharmaceuticals's debt to equity has decreased by 25% from the previous quarter but it has increased by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.